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Comparison of Th1 cytokines and T cell markers gene expressions between virulent and 
an attenuated EIAV vaccine strain 
Talia Henkle, Chong Liu, David W. Horohov. 
Gluck Equine Research Center, University of Kentucky 
Abstract 
The equine infectious anemia virus (EIAV) is closely related to HIV and has been used as 
a model to identify protective mechanisms against lentivirus infection. In horses, EIA 
infection progresses for about a year before infected horses manage to control virus 
replication. This naturally-gained protection is absolutely dependent on active immune 
responses as evidenced by the fact that immunosuppressive drugs can induce the 
recurrence of disease.  As the resolution of initial viremia correlates with the appearance 
of virus specific cytotoxic T lymphocytes (CTL), we believe that cellular immune 
responses play a key role in controlling EIAV in the horse. In a previous study, a 
modified live EIAV stain (D9) provided effective protection against homologous virus 
challenge without causing disease, but this vaccine could not achieve optimum protective 
immunity until six months post vaccination. In this study, development of cell-mediated 
immunity was monitored in EIAVD9 infected ponies over a six-month period. We 
hypothesized that both Th1 cytokines and CTL would be upregulated in EIAVD9 infected 
ponies. To test this hypothesis, ponies were inoculated with the attenuated EIAVD9 strain. 
Whole blood samples were collected into PAXgene™ tubes weekly during the acute 
infection stage (first 6 weeks) and at monthly intervals thereafter corresponding to the 
chronic infection phase. Total RNA was isolated from the PAXgene™ tubes and gene 
expression for both Th1 cytokine (IFN ) and CTL markers (Granzyme B and Perforin) 
were determined using real-time PCR. At the same time, another group of ponies 
receiving a virulent EIAV were monitored and sampled as comparison. We found that 
Th1 cytokine (IFN ) and CTL marker (perforin) genes were significantly increased four 
months post EIAVD9 infection.  These results indicate that the maturation of cellular 
immune response in EIAVD9 infected horses requires at least four months.  
 
1. Introduction 
Modified live or attenuated vaccines have been proven effective at preventing viral 
diseases such as polio, measles, and smallpox (Mims, 1987). Since an attenuated vaccine 
for HIV-1 is desired, work towards this goals has focused on closely related animal 
lentiviruses (Craigo et al., 2007).   
Equine Infectious Anemia Virus (EIAV) is a lentivirus that solely infects equids. EIAV 
causes a globally prevalent chronic infection among equids, which makes the 
development of a vaccine for EIAV an active area of research in equine veterinary 
medicine (Capomaccio et al., 2012a; Capomaccio et al., 2012b; Craigo et al., 2007). 
EIAV is transmitted via blood-feeding insect vectors, or via medical procedures such as 
the use of virally contaminated needles(Capomaccio et al., 2012a; Capomaccio et al., 
2012b). EIAV manifests itself in three stages; acute, chronic, and inapparent. Once 
infected with EIAV, the virus replicates within the equid for about 5 weeks before it can 
be detected. Viremia is usually indicated by a fever, which occurs right before the equid 
tests positive (Coggins Test). The acute signs of EIAV are fever, reduced platelet counts, 
and a mild loss of appetite. The resolution of the acute phase is correlated with the 
appearance of the virus specific cytotoxic T-lymphocytes (CTLs) (Capomaccio et al., 
2012a; Capomaccio et al., 2012b). After approximately 3-4 months the disease progresses 
into the chronic phase which is characterized by recurring fever, pronounced platelet 
reduction, ruptured blood vessels on mucous membranes, anemia, depression, and 
swelling of limbs (Capomaccio et al., 2012a; Capomaccio et al., 2012b; Craigo et al., 
2007).  More than 90% of horses progress into the life-long inapparent carrier phase 8-12 
months post infection (Craigo et al., 2007). In this phase, viral load is tightly controlled 
by the horse’s immune system and the horse becomes asymptomatic of EIAV infection. 
Unlike equids and EIAV, humans possess no natural immunological protection 
mechanisms against their respective lentivirus, HIV, which makes EIAV a unique and 
valuable model for HIV research.  
Over the past twenty years, a wide range of EIAV vaccines have been developed with 
efficacies ranging from sterilizing immunity to profound enhancement of viral replication 
(Craigo et al., 2007). In a previous study, a modified EIAV strain (D9) provided effective 
protection against a homologous virus challenge without causing disease. However, this 
vaccine could not achieve optimum protective immunity until six months post 
vaccination (Craigo et al., 2007). This delay in the development of protective immunity 
indicated that a maturation of the effector mechanism needed to occur.  Analysis of 
longitudinal serum from EIAV infected horses displayed a prolonged evolution of 
envelope-specific antibodies responses, which are represented by avidity index, 
conformational ratio, and neutralization titer, in EIAV infected horses (Hammond, 1997).  
Cellular immune responses also play an important role in controlling EIAV infection as 
the resolution of the acute phase is correlated with the appearance of the virus specific 
CTL (Capomaccio et al., 2012a; Capomaccio et al., 2012b). The cell-mediated immune 
response has not yet been thoroughly studied.  
In this study, we aimed to monitor the kinetics of Th1 and CTL markers gene expressions 
in EIAVD9 infected ponies over six months in order to provide new insights into cellular 
immunity development in EIAVD9 infected ponies.  Perforin and granzyme B are markers 
for CTLs.  Both are located in the secretory granules of activated CTLs.  When CTLs kill 
their target cells, perforin, a pore-forming protein, allows granzyme B to enter the 
infected cell and activate the cellular apoptosis pathway (Lowin et al., 1994).   
 
2. Materials and Methods 
2.1 Experimental setup.  
Eight ponies were inoculated with the EIAVUK strain as the control group and six ponies 
were inoculated with the EIAVD9 vaccine.  Approximately 3.0 ml of whole blood samples 
were collected into PAXgene
™ 
tubes at weekly intervals after inoculation for five weeks 
and then monthly, for three months, 4 months after inoculation. PAXgene
™ 
tubes 
stabilize intracellular RNA in the blood sample. 
2.2 Determination of Th1 cytokine (IFN ) and CTL markers (Granzyme B and 
Perforin) gene expressions.  
After the samples were collected, the tubes were incubated at room temperature for 
approximately 24 hours and then stored at -20 C.  Once ready to be processed the 
samples were thawed. Total RNA was extracted from the samples using the PAXgene
™ 
blood RNA extraction kit (Qiagen, Valencia, CA) using the protocol provided by the 
manufacturer. The samples were then analyzed for RNA concentration using a 
spectrophotometer. 1 g RNA was then dissolved in 41.5 l ribonuclease free water 
(Qiagen, Valencia, CA) and then transcribed into cDNA using 38.5 l of reverse 
transcription master mix (16 l AMV buffer [Promega], 16 l MgCl2 [25mM, Promega], 
4 l dNTP [10mM; Promega], 1 l RNAsin [40 units/ml, Promega] 1 l oligo dT primer 
[0.5 g/ml; Promega], 0.5 l avian myeloblastosis virus [AMV] reverse transcriptase 
[20units/ml; Promega, Madison, WI]), as previously described (Coombs et al., 2006). 
The reaction mixture was incubated at 42 C for 15 min and then 95 C for 5 min. The 
cDNA was stored at -20 C until RT-PCR was performed. 
The cDNA samples were then loaded onto 384-well plates in duplicate wells.  Each well 
contained 4.5 l cDNA and 5.5 l master mix (0.5 l 20  assay mix for primer/probe set of 
interest [Applied Biosystems], and 5 l Sensimix [Bioline, Taunton, MA]) The gene 
expressions of granzyme B, IFN , and perforin were then determined using RT-PCR 
(ABI systems 7900 RT-PCR Instrument, Foster City, CA). The primer/probe sets were all 
equine specific.  The PCR reactions were initially incubated for 10 min at 95 C, followed 
by 40 cycles of 95 C for 15s and 60 C for 60s.  The internal PCR amplification 
efficiencies were calculated in LinReg PCR (Ramakers et al., 2003). to confirm that the 
application efficiencies exceeded 99%. To achieve relative quantification the CT 
method (Schmittgen and Livak, 2008) was utilized to determine any changes in gene 
expression. Beta-glucuronidase ( -GUS) was used as the endogenous control. The 
average of the medium control samples of each horse were calculated and then used as 
the calibrator for each target gene. The Relative quantity (RQ) was calculated using 2
 -
CT
 (Schmittgen and Livak, 2008). Gene expressions over 2 were viewed as positive. 
3. Results 
Th1 cytokines (IFN ) and CTL markers (GrzB and Perforin) genes were significantly 
increased two weeks post infection in pathogenic EIAV infected group (Figure 1). This 
correlates with the time of appearance of CTL response in previous studies. In contrast, 
the EIAVD9 ponies (EIAV attenuated vaccine group) did not show any changes in gene 
expressions early after inoculation. In comparison, IFN  and perforin genes were 
significantly increased four months post infection. This result indicated that the 
maturation of cellular immune responses in D9 infected equines at least 4 months. 
 
 
Figure 1.  Expression of Granzyme B mRNA in EIAV infected and EIAVD9 vaccinated ponies over a five-
month period. 
 
 
Figure 2. Expression or IFNγ mRNA in EIAV infected and EIAVD9 vaccinated ponies over a five-month 
period. 
 
Figure 3.  Expression of perforin mRNA in EIAV infected and EIAVD9 vaccinated over a five-month 
period. 
. 
Discussion:  
The data indicated that the cellular immune system might play an important role in the 
immunological control of EIAV as previously suspected. As previously stated, more than 
90% of EIAV infected equids are able to effectively control viral replication after 8-12 
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months. EIAVD9 infected ponies, show no symptoms of infection (when not immuno-
suppressed) and are able to effectively protect against a challenge with the parental strain 
of EIAV 6 months after vaccination. The EIAVUK virus used in this study has greater 
virulence resulting in higher viral loads post challenge compared to the attenuated D9 
strain. This likely resulted in greater stimulation of the immune response in the EIAVUK 
recipients, as evidence by earlier expression of the immune related genes.  Indeed, there 
was increased expression of both perforin and granzyme B following infection with 
EIAVUK before that seen in the EIAVD9 infected ponies. Nonetheless, the significant 
upregulation of perforin in both groups of ponies at the 4 month mark indicates that 
cellular immunity may be involved in the effective immune response to both viruses.  
Exactly how the cellular immune system may be involved in the control disease is still 
under investigation.  
Understanding the immunological processes that are involved in controlling EIAV 
replication in the inapparent carrier phase as well as horses vaccinated with EIAVD9 could 
have global implications in the control of all lentiviral diseases, including those that are 
prevalent in domestic animals as well as HIV in humans. Compared to pathogenic 
viruses which cause recurring cycling of EIA, this attenuated D9 strain does not 
cause any clinical EIA and could finally reach an optimum protective immunity six 
months post infection. In this study, we found that EIAVD9 infected ponies did not show 
significant IFN  and perforin gene expressions until 4 months post infection. This slow 
development of cellular immunity might correlate with the significantly decreased 
replication of this attenuated virus in horse body (Craigo, 2005; Peng, 2005). Further 
studies underlining the mechanisms related to the development of cellular 
immunity in EIAVD9 infected ponies would provide useful information for improved 
lentivirus vaccine design.  
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